Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents

In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10(th)–11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: June Choe, Young, Yi, Seonju, Hwang, Insob, Kim, Jia, Park, Young-Joon, Cho, Eunhee, Jo, Myoungyoun, Lee, Hyunju, Hwa Choi, Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702409/
https://www.ncbi.nlm.nih.gov/pubmed/35012777
http://dx.doi.org/10.1016/j.vaccine.2021.12.044
Descripción
Sumario:In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10(th)–11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8–3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6–6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6–92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5–99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.

Ejemplares similares